{"id":"cdk4-6","name":"CDK4/6","symbol":"CDK4, CDK6","route":"/targets/cdk4-6/","asOf":"2026-09-04","xrefs":[{"hgnc":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1773","ensembl":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000135446","uniprot":"https://www.uniprot.org/uniprotkb/P11802/entry","alphafold-db":"https://alphafold.ebi.ac.uk/entry/P11802","chembl":"https://www.ebi.ac.uk/chembl/explore/target/CHEMBL331","open-targets":"https://platform.opentargets.org/target/ENSG00000135446","civic":"https://civicdb.org/genes/1019/summary","oncokb":"https://www.oncokb.org/gene/CDK4","cosmic":"https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=CDK4","cbioportal":"https://www.cbioportal.org/results/mutations?cancer_study_list=msk_impact_2017&gene_list=CDK4","depmap":"https://depmap.org/portal/gene/CDK4?tab=overview","human-protein-atlas":"https://www.proteinatlas.org/ENSG00000135446-CDK4","ncbi-gene":"https://www.ncbi.nlm.nih.gov/gene/1019","omim":"https://www.omim.org/entry/123829"},{"hgnc":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1777","ensembl":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000105810","uniprot":"https://www.uniprot.org/uniprotkb/Q00534/entry","alphafold-db":"https://alphafold.ebi.ac.uk/entry/Q00534","chembl":"https://www.ebi.ac.uk/chembl/explore/target/CHEMBL2508","open-targets":"https://platform.opentargets.org/target/ENSG00000105810","civic":"https://civicdb.org/genes/1021/summary","oncokb":"https://www.oncokb.org/gene/CDK6","cosmic":"https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=CDK6","cbioportal":"https://www.cbioportal.org/results/mutations?cancer_study_list=msk_impact_2017&gene_list=CDK6","depmap":"https://depmap.org/portal/gene/CDK6?tab=overview","human-protein-atlas":"https://www.proteinatlas.org/ENSG00000105810-CDK6","ncbi-gene":"https://www.ncbi.nlm.nih.gov/gene/1021","omim":"https://www.omim.org/entry/603368"}],"products":[{"id":"abemaciclib","name":"Abemaciclib","status":"approved","modality":"Small-molecule CDK4/6 inhibitor","route":"/drugs/abemaciclib/"},{"id":"atirmociclib","name":"Atirmociclib","status":"phase-3","modality":"Small-molecule CDK4-selective inhibitor","route":"/drugs/atirmociclib/"},{"id":"avzo-023","name":"AVZO-023","status":"phase-2","modality":"Small-molecule inhibitor","route":"/drugs/avzo-023/"},{"id":"dalpiciclib","name":"Dalpiciclib","status":"approved","modality":"Small-molecule CDK4/6 inhibitor","route":"/drugs/dalpiciclib/"},{"id":"lerociclib","name":"Lerociclib","status":"phase-3","modality":"Oral CDK4/6 inhibitor","route":"/drugs/lerociclib/"},{"id":"palbociclib","name":"Palbociclib","status":"approved","modality":"Small-molecule CDK4/6 inhibitor","route":"/drugs/palbociclib/"},{"id":"ribociclib","name":"Ribociclib","status":"approved","modality":"Small-molecule CDK4/6 inhibitor","route":"/drugs/ribociclib/"},{"id":"tqb3616","name":"TQB3616","status":"phase-3","modality":"small molecule","route":"/drugs/tqb3616/"},{"id":"trilaciclib","name":"Trilaciclib","status":"approved","modality":"Intravenous CDK4/6 inhibitor given before chemotherapy to protect bone marrow","route":"/drugs/trilaciclib/"}],"trials":[{"id":"persevera","name":"persevERA","nct":"NCT04546009","phase":"3","status":"negative"},{"id":"ember-3","name":"EMBER-3","nct":"NCT04975308","phase":"3","status":"positive"},{"id":"patina","name":"PATINA","nct":"NCT02947685","phase":"3","status":"positive"},{"id":"postmonarch","name":"postMONARCH","nct":"NCT05169567","phase":"3","status":"positive"},{"id":"natalee","name":"NATALEE","nct":"NCT03701334","phase":"3","status":"positive"},{"id":"dawna-1","name":"DAWNA-1","nct":"NCT03927456","phase":"3","status":"positive"},{"id":"penelope-b","name":"PENELOPE-B","nct":"NCT01864746","phase":"3","status":"negative"},{"id":"nct02763566","name":"A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer","nct":"NCT02763566","phase":"3","status":"active"},{"id":"monarche","name":"monarchE","nct":"NCT03155997","phase":"3","status":"positive"},{"id":"pallas-penelope-b","name":"PALLAS & PENELOPE-B","nct":"NCT02513394","phase":"3","status":"negative"},{"id":"nct02107703","name":"A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer","nct":"NCT02107703","phase":"3","status":"active"},{"id":"nct02152631","name":"A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer","nct":"NCT02152631","phase":"3","status":"active"},{"id":"monarch-3","name":"MONARCH 3","nct":"NCT02246621","phase":"3","status":"positive"},{"id":"monaleesa-2","name":"MONALEESA-2","nct":"NCT01958021","phase":"3","status":"positive"},{"id":"paloma-2","name":"PALOMA-2","nct":"NCT01740427","phase":"3","status":"mixed"},{"id":"nct04711252","name":"A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease","nct":"NCT04711252","phase":"3","status":"active"},{"id":"nct07647328","name":"A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer","nct":"NCT07647328","phase":"3","status":"recruiting"},{"id":"nct05288166","name":"A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)","nct":"NCT05288166","phase":"3","status":"active"},{"id":"nct05851014","name":"A Study of GB491 in Combination With Letrozole in Patients With HR Positive and HER2 Negative Advanced Breast Cancer","nct":"NCT05851014","phase":"3","status":"recruiting"},{"id":"nct06065748","name":"A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)","nct":"NCT06065748","phase":"3","status":"active"},{"id":"nct04862663","name":"Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)","nct":"NCT04862663","phase":"3","status":"active"},{"id":"nct05780567","name":"Clinical Study on Adjuvant Therapy of TQB3616 Combined With Endocrine Therapy Compared With Placebo Combined With Endocrine Therapy in Patients With Breast Cancer","nct":"NCT05780567","phase":"3","status":"active"},{"id":"nct07473128","name":"Effect of Trilaciclib in the Prevention of Myelosupression in Subjects With Limited-stage Small Cell Lung Cancer","nct":"NCT07473128","phase":"3","status":"recruiting"},{"id":"nct05696626","name":"Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation","nct":"NCT05696626","phase":"3","status":"recruiting"},{"id":"nct05501886","name":"Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)","nct":"NCT05501886","phase":"3","status":"active"},{"id":"nct03784014","name":"Molecular Profiling of Advanced Soft-tissue Sarcomas","nct":"NCT03784014","phase":"3","status":"completed"},{"id":"nct07085767","name":"Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer","nct":"NCT07085767","phase":"3","status":"recruiting"},{"id":"nct06757634","name":"Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)","nct":"NCT06757634","phase":"3","status":"recruiting"},{"id":"nct04842617","name":"Phase III Study ：SHR6390/Placebo Combined With Endocrine Therapy for the Adjuvant Treatment of Hormone Receptor Positive,Human Epidermal Receptor 2 Ne","nct":"NCT04842617","phase":"3","status":"active"},{"id":"nct05827081","name":"Phase IIIb Study of Ribociclib + ET in Early Breast Cancer","nct":"NCT05827081","phase":"3","status":"recruiting"},{"id":"nct06380751","name":"Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer","nct":"NCT06380751","phase":"3","status":"recruiting"},{"id":"nct06760637","name":"Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease","nct":"NCT06760637","phase":"3","status":"active"},{"id":"nct05365178","name":"To Evaluate the Efficacy and Safety of TQB3616 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant in Previously Untreated Hormone-receptor (HR)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Advanced Breast Cancer","nct":"NCT05365178","phase":"3","status":"active"},{"id":"nct05909397","name":"Vepdegestrant (ARV-471/PF-07850327) + Palbociclib vs Letrozole + Palbociclib in ER(+)/HER2(-) Advanced Breast Cancer","nct":"NCT05909397","phase":"3","status":"active"},{"id":"nct03706365","name":"A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer","nct":"NCT03706365","phase":"2/3","status":"active"},{"id":"inavo120","name":"INAVO120","nct":"NCT04191499","phase":"2/3","status":"positive"},{"id":"pediatric-match","name":"NCI-COG Pediatric MATCH (APEC1621)","nct":"NCT03155620","phase":"platform","status":"active"},{"id":"lung-map","name":"Lung-MAP (SWOG S1400 and S1900)","nct":"NCT02154490","phase":"platform","status":"completed"},{"id":"nci-match","name":"NCI-MATCH (EAY131)","nct":"NCT02465060","phase":"platform","status":"active"},{"id":"nct05440786","name":"CAMPFIRE: A Study of Abemaciclib (LY2835219) in Participants With Ewing's Sarcoma","nct":"NCT05440786","phase":"2","status":"active"},{"id":"fourlight-1","name":"FOURLIGHT-1","nct":"NCT06105632","phase":"2","status":"positive"},{"id":"national-lung-matrix-trial","name":"National Lung Matrix Trial","nct":"NCT02664935","phase":"2","status":"completed"},{"id":"tapur","name":"TAPUR (Targeted Agent and Profiling Utilization Registry)","nct":"NCT02693535","phase":"2","status":"recruiting"},{"id":"nct02747004","name":"A Study of Abemaciclib (LY2835219) Plus Tamoxifen or Abemaciclib Alone in Women With Metastatic Breast Cancer","nct":"NCT02747004","phase":"2","status":"active"},{"id":"nct05999994","name":"A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer","nct":"NCT05999994","phase":"2","status":"recruiting"},{"id":"nct07405801","name":"A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer","nct":"NCT07405801","phase":"2","status":"recruiting"},{"id":"nct06413706","name":"A Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following Radiotherapy","nct":"NCT06413706","phase":"2","status":"active"},{"id":"nct07054190","name":"A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Cancer","nct":"NCT07054190","phase":"2","status":"recruiting"},{"id":"nct07441369","name":"Abemaciclib Combined With FOLFOX/FOLFIRI Regimen in Patients With Advanced Colorectal Liver Metastases Cancer","nct":"NCT07441369","phase":"2","status":"recruiting"},{"id":"nct06365788","name":"Bicalutamide and Abemaciclib in Inoperable or Metastatic Androgen Receptor-positive Triple-negative Breast Cancer","nct":"NCT06365788","phase":"2","status":"recruiting"},{"id":"nct07255612","name":"Bone Marrow Protection, Safety, Efficacy of Trilaciclib and Eribulin in Locally Advanced or Metastatic TNBC(Triple-negative Breast Cancer)","nct":"NCT07255612","phase":"2","status":"planned"},{"id":"nct05067530","name":"Cyclin dEpendent Kinase in tRiple nEGatIVe brEast canceR - a \"Window of Opportunity\" Study","nct":"NCT05067530","phase":"2","status":"planned"},{"id":"nct04567420","name":"DNA-guided Second Line Adjuvant Therapy for High Residual Risk, Estrogen Receptor Positive, HER-2 Negative Breast Cancer (DARE)","nct":"NCT04567420","phase":"2","status":"active"},{"id":"nct06698965","name":"Efficacy and Safety of First-line Treatment for Extensive-stage Small Cell Lung Cancer Using a Combination Therapy of Trilaciclib, Envafolimab, Etoposide, and C","nct":"NCT06698965","phase":"2","status":"recruiting"},{"id":"nct06702618","name":"Evaluation of TQB3616 Capsules in a Phase II Clinical Trial for Recurrent/Metastatic Breast Cancer","nct":"NCT06702618","phase":"2","status":"active"},{"id":"nct07340541","name":"Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies","nct":"NCT07340541","phase":"2","status":"recruiting"},{"id":"nct05463601","name":"Mecapegfilgrastim for the Prevention of Dalpiciclib -Induced Neutropenia in Advanced Breast Cancer","nct":"NCT05463601","phase":"2","status":"active"},{"id":"nct04553133","name":"PF-07104091 as a Single Agent and in Combination Therapy","nct":"NCT04553133","phase":"2","status":"active"},{"id":"nct07605728","name":"Probiotics for Abemaciclib-Induced Abdominal Discomfort.","nct":"NCT07605728","phase":"2","status":"recruiting"},{"id":"nct05226871","name":"Study for Participants Continuing From Pfizer-sponsored Palbociclib (a Study Medicine) Studies","nct":"NCT05226871","phase":"2","status":"active"},{"id":"nct04417621","name":"Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma","nct":"NCT04417621","phase":"2","status":"active"},{"id":"nct03709680","name":"Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors","nct":"NCT03709680","phase":"2","status":"active"},{"id":"nct04606446","name":"Study of PF-07248144 in Advanced or Metastatic Solid Tumors","nct":"NCT04606446","phase":"2","status":"recruiting"},{"id":"nct05578326","name":"Study of Trilaciclib and Lurbinectidin","nct":"NCT05578326","phase":"2","status":"recruiting"},{"id":"nct07427394","name":"Study to Evaluate the Safety and Tolerability of Camizestrant in Combination With Atirmociclib in Women With Advanced Breast Cancer","nct":"NCT07427394","phase":"2","status":"recruiting"},{"id":"nct05725200","name":"Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer","nct":"NCT05725200","phase":"2","status":"recruiting"},{"id":"nct04557449","name":"Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors","nct":"NCT04557449","phase":"2","status":"active"},{"id":"nct06370416","name":"the Prevention of Bone Marrow Suppression Caused by Chemotherapy in Advanced NSCLC With Trilaciclib","nct":"NCT06370416","phase":"2","status":"recruiting"},{"id":"nct05862610","name":"The Study of Trilaciclib Combined With Chemotherapy On The Neoadjuvant Therapy of TNBC","nct":"NCT05862610","phase":"2","status":"planned"},{"id":"nct06813079","name":"Using Tumor Models to Determine Treatments","nct":"NCT06813079","phase":"2","status":"recruiting"},{"id":"nct06208410","name":"A Clinical Study of JS105 in Combination With Other Anti-tumor Therapies in Patients With Solid Tumors","nct":"NCT06208410","phase":"1/2","status":"recruiting"},{"id":"nct06188520","name":"A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With ","nct":"NCT06188520","phase":"1/2","status":"recruiting"},{"id":"nct07002177","name":"A Phase Ib/II Study to Evaluate Multiple Combination Therapies of FWD1802 in Patients With ER+/HER2- BC","nct":"NCT07002177","phase":"1/2","status":"recruiting"},{"id":"nct04802759","name":"A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer","nct":"NCT04802759","phase":"1/2","status":"recruiting"},{"id":"nct05468697","name":"A Study of Belzutifan (MK-6482) in Combination With Palbociclib Versus Belzutifan Monotherapy in Participants With Advanced Renal Cell Carcinoma (MK-6","nct":"NCT05468697","phase":"1/2","status":"active"},{"id":"nct06202261","name":"A Study of TQB2930 for Injection Monotherapy or Combination Therapy in Patients With Recurrent/Metastatic Breast Cancer","nct":"NCT06202261","phase":"1/2","status":"recruiting"},{"id":"nct07100106","name":"A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer","nct":"NCT07100106","phase":"1/2","status":"recruiting"},{"id":"nct05262400","name":"A Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid Tumors","nct":"NCT05262400","phase":"1/2","status":"active"},{"id":"nct06206837","name":"A Study to Learn About Vepdegestrant When Given With PF-07220060 to People With Advanced or Metastatic Breast Cancer.","nct":"NCT06206837","phase":"1/2","status":"active"},{"id":"nct06167694","name":"Clinical Study of HRS-8080 in Combination With Dalpiciclib Isethionate Tablets in Patients With Unresectable or Metastatic Breast Cancer","nct":"NCT06167694","phase":"1/2","status":"recruiting"},{"id":"nct05768139","name":"First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors","nct":"NCT05768139","phase":"1/2","status":"recruiting"},{"id":"nct05735080","name":"Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer","nct":"NCT05735080","phase":"1/2","status":"recruiting"},{"id":"nct05563220","name":"Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Cancer","nct":"NCT05563220","phase":"1/2","status":"active"},{"id":"nct06998407","name":"ORION-1: Study of AVZO-023 as a Single Agent and in Combination With AVZO-021, and/or Endocrine Therapy in Advanced Solid Tumors","nct":"NCT06998407","phase":"1/2","status":"recruiting"},{"id":"nct05573126","name":"Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer","nct":"NCT05573126","phase":"1/2","status":"recruiting"},{"id":"nct05358249","name":"Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation","nct":"NCT05358249","phase":"1/2","status":"active"},{"id":"nct06810544","name":"Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss","nct":"NCT06810544","phase":"1/2","status":"recruiting"},{"id":"nct06736704","name":"SNV4818 in Participants With Advanced Solid Tumors","nct":"NCT06736704","phase":"1/2","status":"recruiting"},{"id":"nct05386108","name":"Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer","nct":"NCT05386108","phase":"1/2","status":"recruiting"},{"id":"nct05867251","name":"Study of AVZO-021 in Patients With Advanced Solid Tumors","nct":"NCT05867251","phase":"1/2","status":"recruiting"},{"id":"nct06726148","name":"Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors","nct":"NCT06726148","phase":"1/2","status":"recruiting"},{"id":"nct05548127","name":"TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study A)","nct":"NCT05548127","phase":"1/2","status":"active"},{"id":"nct05573555","name":"TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study B)","nct":"NCT05573555","phase":"1/2","status":"active"},{"id":"zen-3694-abemaciclib-nut","name":"ZEN-3694 with abemaciclib in NUT carcinoma, breast cancer and other solid tumours (NCI phase 1)","nct":"NCT05372640","phase":"1","status":"recruiting"}],"pathways":["bladder-cancer-signalling","breast-cancer-signalling","senescence","dna-replication-licensing","glioma-signalling","melanoma-signalling","nsclc-signalling","er-signaling","oncogenic-viruses","p53-cell-cycle","pancreatic-cancer-signalling","sclc-signalling","cell-cycle-engine-cdks"],"companies":["avenzo","circle-pharma","eli-lilly","g1-therapeutics","hengrui","kymera","novartis","pfizer","pharmacosmos","sino-biopharm"],"keyPapers":["paper-natalee-nejm-2024","paper-monarche-jco-2020","paper-herschkowitz-rb1-loss-basal-like-bcr-2008","paper-sherr-roberts-cdk-inhibitors-genesdev-1999","paper-el-deiry-waf1-p21-cell-1993"],"hotspots":[],"openQuestions":[{"id":"cdk46-after-progression","question":"After progression on a CDK4/6 inhibitor, does continuing CDK4/6 inhibition with a new endocrine partner beat switching to a targeted or antibody-drug conjugate approach?","stage":"clinical","actor":"clinic","source":{"label":"postMONARCH (ClinicalTrials.gov)","url":"https://clinicaltrials.gov/study/NCT05169567"}}],"assays":[{"id":"ki67-mib1","name":"Ki-67 IHC (MIB-1)","cutoff":"At least 20% (monarchE high-risk cohort; the abemaciclib label's Ki-67 requirement was removed in 2023)"}],"resistance":[{"class":"cdk46-endocrine","mechanism":"ESR1 ligand-binding-domain mutations","category":"on-target"},{"class":"cdk46-endocrine","mechanism":"RB1 loss","category":"bypass"},{"class":"cdk46-endocrine","mechanism":"Cyclin E / CDK2 activation","category":"bypass"},{"class":"cdk46-endocrine","mechanism":"PI3K/AKT/mTOR activation","category":"bypass"}],"licence":"CC BY-NC 4.0, attribution to OnCo (https://onco.cc); commercial use needs a licence"}